Turinabol (4-chlorodehydromethyltestosterone) manufactured by Genesis is an advanced oral anabolic-androgenic steroid designed for athletes prioritizing high-density lean muscle gains, explosive strength, and athletic endurance without unwanted fluid retention. Structurally related to methandrostenolone, Turinabol features a crucial 4-chloro alteration that permanently eliminates aromatization, ensuring complete absence of estrogenic side effects such as gynecomastia and extracellular water pooling. When looking for genuine performance enhancement, athletes choose our premium Turinabol selection for clinically verified purity and bioavailability.
Turinabol exhibits a strong anabolic affinity while maintaining a low androgenic profile (anabolic/androgenic ratio: 54:6). This chemical characteristic promotes steady protein synthesis, nitrogen retention within skeletal muscle tissue, and accelerated glycogen recovery without triggering severe androgenic consequences. Moreover, 4-chlorodehydromethyltestosterone significantly decreases serum Sex Hormone-Binding Globulin (SHBG) levels, thereby increasing free circulating concentrations of other co-administered anabolic agents.
Due to its active elimination half-life of roughly 16 hours, daily administration can be divided into two equal doses (morning and late afternoon) to ensure stable plasma concentrations. A standard cycle typically spans 6 to 8 weeks to maximize athletic performance while mitigating hepatic stress:
Turinabol Genesis excels in both cutting and lean bulking stacks. It pairs exceptionally well with non-aromatizing injectables such as Primobolan, Masteron, or moderate doses of Testosterone Enanthate. Because Turinabol lowers circulating SHBG, it exerts a synergistic effect, multiplying the free anabolic potential of secondary compounds in a multi-compound cycle.
Although it does not convert to estrogen, Turinabol suppresses the Hypothalamic-Pituitary-Testicular Axis (HPTA). Comprehensive PCT is essential upon completion of a cycle. Standard protocols involve SERMs such as Clomiphene (Clomid) at 50 mg/day for 3–4 weeks and Tamoxifen (Nolvadex) at 20 mg/day. As an oral 17-alpha-alkylated steroid, hepatic protection using TUDCA or NAC alongside routine lipid panel and liver enzyme checks is strongly recommended throughout the protocol.
No. Due to the 4-chloro substitution on its molecular ring, Turinabol cannot interact with the aromatase enzyme. It generates completely dry, dense muscle tissue with zero direct risk of estrogen-mediated gynecomastia or fluid retention.
Yes. Turinabol is a 17-alpha-alkylated oral steroid, which means it resists first-pass liver metabolism and exerts mild to moderate hepatotoxicity. Co-administering liver support agents such as TUDCA or NAC and limiting cycles to 6–8 weeks is medically advised.
Athletes typically report noticeable increases in muscular endurance, workout volume capacity, and hardness within the first 10 to 14 days, followed by consistent, clean gains in lean tissue throughout the remainder of the 6-to-8-week protocol.
